Patents by Inventor Glen S. Kwon
Glen S. Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10980891Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.Type: GrantFiled: October 25, 2019Date of Patent: April 20, 2021Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Yu Tong Tam
-
Patent number: 10828372Abstract: Described herein is a mono-end PEGyated functional upstream domain (FUD), pharmaceutical compositions, and its use to inhibit fibrosis such as organ fibrosis, idiopathic pulmonary fibrosis and fibrosis associated with cancer. Also included are methods of probing for injured or repairing tissue in an individual in need thereof using the mono-end PEGyated-FUD.Type: GrantFiled: November 12, 2018Date of Patent: November 10, 2020Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Bianca R. Tomasini-Johansson, Glen S. Kwon, Pawel Waldemar Zbyszynski, Nathan Sandbo, Ksenija Bernau
-
Publication number: 20200261583Abstract: The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Applicant: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Hyunah Cho
-
Patent number: 10682415Abstract: The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.Type: GrantFiled: July 22, 2014Date of Patent: June 16, 2020Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Glen S. Kwon, Hyunah Cho
-
Publication number: 20200054758Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.Type: ApplicationFiled: October 25, 2019Publication date: February 20, 2020Applicant: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Yu Tong Tam
-
Patent number: 10456477Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.Type: GrantFiled: March 13, 2017Date of Patent: October 29, 2019Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Glen S. Kwon, Yu Tong Tam
-
Publication number: 20190142956Abstract: Described herein is a mono-end PEGyated functional upstream domain (FUD), pharmaceutical compositions, and its use to inhibit fibrosis such as organ fibrosis, idiopathic pulmonary fibrosis and fibrosis associated with cancer. Also included are methods of probing for injured or repairing tissue in an individual in need thereof using the mono-end PEGyated-FUD.Type: ApplicationFiled: November 12, 2018Publication date: May 16, 2019Inventors: BIANCA R. TOMASINI-JOHANSSON, GLEN S. KWON, PAWEL WALDEMAR ZBYSZYNSKI, NATHAN SANDBO, KSENIJA BERNAU
-
Publication number: 20190083633Abstract: The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods of preparing and using such compositions to treat various cancers. Specifically, there are provided oligolactic acid conjugates wherein the oligolactic acid comprises 2 to 24 lactic acid subunits and is attached through an ester linkage to the oxygen of the 7-hydroxyl of the paclitaxel or paclitaxel derivative, the 40-hydroxyl of the rapamycin or rapamycin derivative, and the 2?-hydroxyl of the selumetinib or selumetinib derivative. Compositions comprising water and a micelle comprising a polylactic acid-containing polymer and the oligolactic acid conjugate may be readily prepared. Methods of inhibiting or killing cancer cells and treating paclitaxel, rapamycin, and/or selumetinib cancers are also provided.Type: ApplicationFiled: March 13, 2017Publication date: March 21, 2019Inventors: Glen S. Kwon, Yu Tong Tam
-
Publication number: 20180153849Abstract: Provided is a method of treatment including administering to lung, brain or esophageal cancer cells an effective amount of radiation in conjunction with a micelle composition that includes an effective amount of paclitaxel, and one or both of 17-AAG, and rapamycin, wherein the micelle includes poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA).Type: ApplicationFiled: June 10, 2016Publication date: June 7, 2018Inventors: Glen S. KWON, Keishiro TOMODA, Kevin KOZAK
-
Publication number: 20170290852Abstract: The present technology relates generally to micelle formulations of amphotericin B that optionally include 5-fluorocytosine and methods of preparing such formulations. Methods of treating fungal infections with the present compositions are also provided.Type: ApplicationFiled: April 7, 2017Publication date: October 12, 2017Inventor: Glen S. KWON
-
Patent number: 9107814Abstract: Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.Type: GrantFiled: April 30, 2012Date of Patent: August 18, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Marcus L. Forrest
-
Patent number: 8945627Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.Type: GrantFiled: May 4, 2012Date of Patent: February 3, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Ho-Chul Shin, Hyunah Cho
-
Publication number: 20150025106Abstract: The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.Type: ApplicationFiled: July 22, 2014Publication date: January 22, 2015Inventors: Glen S. Kwon, Hyunah Cho
-
Patent number: 8900562Abstract: The present invention provides semi-fluorinated block copolymers and related methods of synthesizing and using semi-fluorinated block copolymers for drug delivery and drug formulation applications. Semi-fluorinated block copolymers of this aspect of the invention include block copolymers having discrete hydrophilic, fluorophilic and hydrophobic structural domains that are capable of forming supramolecular structures in aqueous solutions, such as micelles, for encapsulating hydrophobic and/or fluorophilic therapeutic agents. Encapsulation by semi-fluorinated block copolymers of the present invention allows for enhanced solubilization and stabilization of hydrophobic and/or fluorophilic therapeutic agents relative to conventional drug delivery compositions and methods.Type: GrantFiled: January 10, 2008Date of Patent: December 2, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Sandro Mecozzi, Glen S. Kwon
-
Patent number: 8858965Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.Type: GrantFiled: August 30, 2013Date of Patent: October 14, 2014Assignee: Wisconsin Alumni Research FoundationInventor: Glen S. Kwon
-
Publication number: 20140072602Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.Type: ApplicationFiled: August 30, 2013Publication date: March 13, 2014Applicant: Wisconsin Alumni Research FoundationInventor: Glen S. KWON
-
Patent number: 8529917Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-DMAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-DMAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.Type: GrantFiled: February 26, 2013Date of Patent: September 10, 2013Assignee: Wisconsin Alumni Research FoundationInventor: Glen S. Kwon
-
Patent number: 8383136Abstract: The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.Type: GrantFiled: July 6, 2012Date of Patent: February 26, 2013Assignee: Wisconsin Alumni Research FoundationInventor: Glen S. Kwon
-
Publication number: 20120321715Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.Type: ApplicationFiled: May 4, 2012Publication date: December 20, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, Ho-Chul Shin, Hyunah Cho
-
Publication number: 20120309780Abstract: Hydrophobic drugs become more practical for treatments by being encapsulated in micelle compositions for increasing solubility. Micelle compositions may include an excipient tocopherol and/or prodrug formulations of the drug. Micelles extend the time period the drug remains in the micelles to improve drug circulation time and thereby drug delivery. Hydrophobic drugs for micelle encapsulation may include rapamycin, geldanamycin, and paclitaxel. Administration of these micelle compositions does not require Cremophor EL or Tween 80, avoiding serious side effects associated with these products which would previously accompany such drug administration.Type: ApplicationFiled: April 30, 2012Publication date: December 6, 2012Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Glen S. Kwon, Marcus L. Forrest